From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025
USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...
Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist
Truist lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $18 from $21 but keeps a Buy rating on the shares after its Q4 results ...
Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 The Company established two business units in January 2025 aimed to accelerate the clin ...
The Manila Times11d
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 ; The Company established two business units in January 2025 aimed ...
Finanznachrichten12d
Y-mAbs Therapeutics, Inc.: Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...
snmjournals.org16d
Development and Preclinical Evaluation of
Journal of Nuclear Medicine February 2025, jnumed.124.268835; DOI: https://doi.org/10.2967/jnumed.124.268835 ...
Frontiers26d
An overview of current phase 3 radiopharmaceutical therapy clinical trials
1 Comprehensive Cancer Center Eugène Marquis, Rennes, France 2 Univ Rennes, Inrae, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer) – UMR_A 1341, UMR_S 1241, Rennes, France Over the past ...